– Peter M. Strumph, Chief Executive Officer
– Brendan Classon PhD, Executive Vice President, Research and Development
– Louis Demers, Vice President of Technical Operations
– Matthew J. Hogan, member of the Board of Directors
Parvus Therapeutics, a biopharmaceutical company focused on the development of medicines using the proprietary platform-based, disease-specific immunoregulator, Navacims™, to treat autoimmune diseases without impairing normal immunity, today announced the appointment of Peter Strumph as Chief Executive Officer and a member of the Board of Directors, Matthew J. Hogan as a member of the Board of Directors, Brendan Classon as Executive Vice President, Research and Development, and Louis Demers as Vice President of Technical Operations.
“Parvus’ Navacim technology has the…